文献速递真菌感染医院感染防控

曲霉Usti组所致侵袭性曲霉病:多中心回顾性研究

Invasive Aspergillosis Due to Aspergillus Section Usti: A Multicenter Retrospective Study.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该多中心回顾性研究在8国22家医院识别90例临床标本分离出Usti组曲霉的患者,其中27例符合确诊/临床诊断侵袭性曲霉病,结合文献45例共72例分析。病例多为非中性粒细胞减少的移植受者,肺外受累常见,24周死亡率58%,A. calidoustus最常见,伏立康唑MIC90为8 µg/mL。

要点

  • Usti组侵袭性曲霉病多见于非中性粒细胞减少的移植受者。
  • 肺外受累常见,皮肤受累见于28%病例。
  • 24周死亡率58%,伏立康唑MIC90为8 µg/mL。

核心结论

  • Usti组曲霉所致侵袭性曲霉病主要发生于非中性粒细胞减少的移植患者,常伴肺外感染,死亡率高,最佳抗真菌方案尚待确定。

研究设计与样本

  • 多中心回顾性研究,在8个国家22家医院识别临床标本分离出Usti组曲霉的患者90例,其中27例符合确诊/临床诊断侵袭性曲霉病。
  • 通过文献复习补充45例,共72例确诊/临床诊断侵袭性曲霉病纳入分析。
  • 对可获得的分离株进行菌种鉴定(BenA/CaM测序)和抗真菌药敏试验。

主要发现

  • 造血干细胞移植受者和实体器官移植受者分别占47%和33%。
  • 诊断时仅8%患者中性粒细胞减少,47%病例正在接受抗霉菌预防。
  • 肺部侵袭性曲霉病占67%,原发或继发肺外感染部位占46%,其中皮肤受累占28%。
  • 67%病例使用多种抗真菌药物(序贯或联合)。
  • 24周死亡率为58%,A. calidoustus为最常见病原。

关键数值与推荐

  • 对90%分离株的最低抑菌浓度(MIC90):两性霉素B为1 µg/mL,伏立康唑为8 µg/mL,泊沙康唑为>16 µg/mL,艾沙康唑为4 µg/mL。

临床怎么用

  • 对移植受者出现侵袭性曲霉病时应考虑Usti组曲霉可能,尤其非中性粒细胞减少且伴肺外(如皮肤)受累者。
  • 伏立康唑对Usti组曲霉MIC90较高,经验性用药需结合药敏结果,最佳方案尚待确定。

局限性

  • 回顾性研究设计,部分病例来自文献复习,可能存在选择偏倚。
  • 并非所有分离株均完成菌种鉴定和药敏试验。
  • 最佳抗真菌治疗方案尚无法确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aspergillus spp. of section Usti (A. ustus) represent a rare cause of invasive aspergillosis (IA). This multicenter study describes the epidemiology and outcome of A. ustus infections. METHODS: Patients with A. ustus isolated from any clinical specimen were retrospectively identified in 22 hospitals from 8 countries. When available, isolates were sent for species identification (BenA/CaM sequencing) and antifungal susceptibility testing. Additional cases were identified by review of the literature. Cases were classified as proven/probable IA or no infection, according to standard international criteria. RESULTS: Clinical report forms were obtained for 90 patients, of whom 27 had proven/probable IA. An additional 45 cases were identified from literature review for a total of 72 cases of proven/probable IA. Hematopoietic cell and solid-organ transplant recipients accounted for 47% and 33% cases, respectively. Only 8% patients were neutropenic at time of diagnosis. Ongoing antimold prophylaxis was present in 47% of cases. Pulmonary IA represented 67% of cases. Primary or secondary extrapulmonary sites of infection were observed in 46% of cases, with skin being affected in 28% of cases. Multiple antifungal drugs were used (consecutively or in combination) in 67% of cases. The 24-week mortality rate was 58%. A. calidoustus was the most frequent causal agent. Minimal inhibitory concentrations encompassing 90% isolates (MIC90) were 1, 8, >16, and 4 µg/mL for amphotericin B, voriconazole, posaconazole, and isavuconazole, respectively. CONCLUSIONS: Aspergillus ustus IA mainly occurred in nonneutropenic transplant patients and was frequently associated with extrapulmonary sites of infection. Mortality rate was high and optimal antifungal therapy remains to be defined.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Glampedakis E, Cassaing S, Fekkar A, et al. Invasive Aspergillosis Due to Aspergillus Section Usti: A Multicenter Retrospective Study. Clin Infect Dis. 2021. PMID: 32155262. doi:10.1093/cid/ciaa230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。